Baker McKenzie has advised Servier, and Fenwick & West has advised Day One Biopharmaceuticals. Wilson Sonsini Goodrich & Rosati advised Day One on IP matters related...
Servier to Acquire Day One Biopharmaceuticals in $2.5 Billion Transaction
BioAge Labs Completes $115 Million Upsized Public Offering
Fenwick & West has advised BioAge Labs, Inc. Cooley LLP has represented the underwriters. BioAge Labs, Inc., a clinical-stage biopharmaceutical company (Nasdaq: BIOA), has completed an...
Day One Biopharmaceuticals to Acquire Mersana Therapeutics in Transaction Valued Up to $285 Million
Wilmer Cutler Pickering Hale and Dorr has advised Mersana Therapeutics. Fenwick & West has advised Day One Biopharmaceuticals. Wilson Sonsini Goodrich & Rosati advised Day One...
BioAge Labs’ $238 Million Upsized Initial Public Offering
Fenwick & West represented BioAge Labs, Inc. in the offering, and Cooley represented the underwriters. BioAge Labs, Inc. (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic...
Eli Lilly’s $3.2 Billion Acquisition of Morphic Holdings
Fenwick & West represented Morphic Holdings, Inc. in the transaction, and Kirkland & Ellis represented Eli Lilly and Company. Eli Lilly and Company (NYSE: LLY) announced...
Stoke Therapeutics’ $125 Million Upsized Common Stock Offering
Fenwick & West advised Stoke Therapeutics on the offering, Wilson Sonsini Goodrich & Rosati advised Stoke on IP matters and Davis Polk & Wardwell advised the...
Standard BioTools’ Merger with SomaLogic
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo advised Standard BioTools Inc. on the transaction, and Fenwick & West advised SomaLogic, Inc. Standard BioTools Inc. (Nasdaq: LAB) and SomaLogic (Nasdaq:...
Neurogene’s Merger with Neoleukin
Gibson Dunn & Crutcher LLP is serving as legal counsel to Neurogene Inc. and Fenwick & West LLP is serving as legal counsel to Neoleukin Therapeutics,...
Day One Biopharmaceuticals’ $150 Million Public Offering
Fenwick represented Day One Biopharmaceuticals, Inc. on the offering, while Cooley LLP represented the underwriters. Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company focused...
Morphic Therapeutic’s $276 Million Public Offering
Fenwick represented Morphic Holding, Inc. on the deal. Morphic Holding, Inc. (Nasdaq: MORF), a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment...
DexCom’s $1.25 Billion Convertible Notes Offering and Capped Call Transactions
Fenwick advised DexCom on the offering, while Davis Polk advised the representatives of the initial purchasers and the counterparties to the capped call transactions. DexCom, Inc....
Workday’s $3 Billion Senior Notes Offering
Davis Polk advised the joint book-running managers in the offering while Fenwick represented Workday. Workday, Inc. executed an $3 billion SEC-registered debt offering. The offering consisted of $1...